Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Clovis

- PMLiVE

BMS unveils long-term results for Opdivo in kidney cancer

Results include updated data for Opdivo with or without Yervoy

- PMLiVE

Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls

BMS share price up by 3% on the back of results

Bristol Myers Squibb logo

Another blow for BMS in first-line NSCLC as it pulls EU filing

Opdivo/Yervoy combination is still under review with the FDA

Bristol Myers Squibb logo

FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC

A verdict is expected to be delivered by 15 May

- PMLiVE

Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer

If approved would become first targeted therapy for tumour type

Bristol Myers Squibb logo

BMS expands collaboration with Nektar, sending shares soaring

Adds research programmes in an additional two cancer types

Life with multiple myeloma – why I’m a lucky man living the dream

Multiple myeloma patient Bob Munro explains what it's like to live with the rare blood cancer and how his diagnosis led him on the journey of a lifetime – cycling...

Blue Latitude Health

Bristol Myers Squibb logo

BMS’ Opdivo/Yervoy combination fails to shine in melanoma

Combo therapy did not show significant benefit in key patient population

Bristol Myers Squibb logo

BMS scores FDA priority review for Opdivo/Yervoy combo in liver cancer

Possible new treatment for difficult to treat cancer type

Bristol Myers Squibb logo

BMS’ Opdivo stalls in Q3, but overall figures still top expectations

Group sales rose 6% to $6bn in the third quarter

- PMLiVE

AZ’s Imfinzi combo scores in front-line lung cancer

Attempts to catch up to BMS and Merck in non-small cell lung cancer

Bristol Myers Squibb logo

BMS’ Opdivo/Yervoy combo scores in front-line lung cancer

Makes case for duo therapy in NSCLC patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links